A Phase 1, Randomized, Placebo- Controlled, Double-Blind Safety, Tolerability, Pharmacokinetic, and Exploratory Pharmacodynamic Study in Healthy Subjects and Subjects With Stable Schizophrenia After Multiple Doses of ITI-214
Phase of Trial: Phase I
Latest Information Update: 27 Apr 2018
Price : $35 *
At a glance
- Drugs ITI 214 (Primary)
- Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
- Focus Adverse reactions
- Sponsors Takeda
- 27 Apr 2018 Results presented at the 70th Annual Meeting of the American Academy of Neurology
- 18 Feb 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
- 28 Jul 2014 Planned number of patients changed from 64 to 76 as reported by ClinicalTrials.gov.